Early occurrence of inspiratory muscle weakness in Parkinson's disease

PLoS One. 2018 Jan 12;13(1):e0190400. doi: 10.1371/journal.pone.0190400. eCollection 2018.

Abstract

Introduction: In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of patients with advanced PD. The objective of the present study was to characterize lung function (under off-drug conditions) in early-stage PD patients at baseline and then again two years later.

Methods: Forty-one early-stage PD patients (mean ± SD age: 61.7 ± 7.7; mean ± SD disease duration: 1.9 ± 1.7 years) were prospectively enrolled and compared with 36 age-matched healthy controls. Neurological evaluations and pulmonary function testing were performed in the off-drug condition at the inclusion visit and then two years later.

Results: Pulmonary function testing did not reveal any restrictive or obstructive disorders; at baseline, inspiratory muscle weakness was the only abnormality observed in the PD group (in 53.7% of the patients, vs. 25% in controls; p = 0.0105). The PD patients had a lower mean maximal inspiratory mouth pressure than controls and a lower sniff nasal inspiratory pressure. Two years after the initiation of chronic treatment with antiparkinsonian medications, the maximal inspiratory mouth pressure and the sniff nasal inspiratory pressure tended to be higher. Lastly, overall motor outcomes were not significantly worse in patients with inspiratory muscle weakness than in patients without inspiratory muscle weakness.

Conclusion: Inspiratory muscle weakness seems to be common in patients with early-stage PD, and was seen to be stable over a two-year period. Additional long-term follow-up studies are required to specify the impact of this new feature of PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Inhalation
  • Male
  • Middle Aged
  • Muscle Weakness / physiopathology*
  • Parkinson Disease / physiopathology*
  • Respiratory Muscles / physiopathology*

Grants and funding

This study was founded by the French Association France Parkinson in 2011. Caroline MOREAU is scientific advisor for Abbvie, Medtronics et Bial. David Devos is scientific advisor for Orkyn, Aguettant, Apopharma. Luc Defebvre is scientific advisor for Abbvie, Zambon, Aguettant. Thierry perez, Valerie DEKEN and Guillaume Baille have nothing to disclose.